Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14308952 | 0.75 | SNCA (0.45) | SNCAADORA2AADORA1CLK1 | |
| SCHEMBL21147085 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1CLK1 | |
| SCHEMBL28837183 | 0.69 | ADORA2A (0.39) | SNCAADORA2AADORA1 | |
| SCHEMBL5076877 | 0.68 | CA12 (0.42) | SNCAADORA2AADORA1 | |
| SCHEMBL575029 | 0.67 | DAO (0.53) | — | |
| SCHEMBL20004561 | 0.65 | SNCA (0.42) | SNCA | |
| SCHEMBL29431210 | 0.65 | SNCA (0.42) | SNCA | |
| SCHEMBL22537725 | 0.63 | SNCA (0.73) | SNCA | |
| SCHEMBL30370545 | 0.62 | AXL (0.45) | — | |
| SCHEMBL20683899 | 0.61 | TYRO3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
| WO-2018055316-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | SNCA 4/4885ADORA2A 1424/4885ADORA1 1358/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | SNCA 2/4885ADORA2A 1575/4885ADORA1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.